BIONEUTRAL

BIO EV/EBITDA Analysis

21.0x

Higher than 65% of Healthcare sector peers

Updated 413h ago·SEC filings & market data

Key Takeaway

EV/EBITDA is a valuation ratio that compares a company’s enterprise value to its earnings before interest, taxes, depreciation, and amortization — essentially how many years of cash earnings it would take to buy the whole business.

Sector Performance

65th percentile

BIO

21.0x

Sector Median

15.7x

Sector Avg

29.2x

Prior Period

19.5x(Jul 2026)

↓ Declining

📊

Deep Analysis

At 21.0x, Bio-Rad trades above the healthcare sector median of 16.1x, placing it in the 65th percentile among peers, meaning it is pricier than most comparable companies. The year-over-year change is not available, but the quarter-over-quarter change shows the multiple rose by 7.9%, from 19.5x to 21.0x, indicating recent valuation expansion. This combination of a high level and a rising trend suggests added risk if earnings fail to keep pace, though it also reflects market confidence in future growth. For an investor, the premium valuation leaves less margin for error, making the stock more sensitive to negative news. This metric supports the overall NEUTRAL verdict — it neither confirms a clear bargain nor signals an overvalued extreme, so a balanced stance fits.

Frequently Asked Questions

What does the EV/EBITDA tell investors about BIO?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does BIO's EV/EBITDA compare to its sector?

BIO's EV/EBITDA of 21.0x compares to a Healthcare sector median of 15.7x, placing it in the 65th percentile.

Who are BIO's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: CAH (14.4x), RVTY (17.0x), DGX (14.3x), AMGN (14.0x), ALGN (13.5x).

📚

Learn More About EV/EBITDA

EV/EBITDA Explained: The Valuation Metric Pro Investors Actually Use

Learn what EV/EBITDA is, why it beats P/E for capital-heavy companies, typical sector ranges, and key limitations every serious investor should know.

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.